1. Scrip

Hengrui Renews Global Phase III Push As China Players Plan Pivotal Multinational Trials

 
• By Dexter Jie Yan

After a more than three-year hiatus, China's Hengrui has signalled its return to multiregional Phase III trials as it looks to globalize its innovative pipeline. Meanwhile, a number of other Chinese players have announced plans to kick off Phase III trials this year and beyond.

Hengrui is making a comeback to the stage of global Phase III clinical studies. (Shutterstock)

Jiangsu Hengrui Pharmaceuticals, China’s top innovative drug maker by pipeline size, is set to spring back into the high-stakes arena of global Phase III clinical trials which include sites in the US and elsewhere after holding off on such activity for more than three years.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from R&D